Every time an AI alert is sent,Kangtai Biotechnology (SZ 300601, closing price: 81.48 yuan) released a performance forecast on the evening of April 13. It is expected that the net profit attributable to shareholders of listed companies in the first quarter of 2022 will be 250 million to 300 million yuan, a year-on-year increase of 893.93% to 1092.72% The main reason for the change in performance is that, during the reporting period, the company actively carried out various tasks in accordance with the annual business plan to be market-oriented, promoted product research and development and production in an orderly manner, further strengthened market sales and promotion, and achieved a good growth trend in business performance. . In the first quarter of 2022, the sales revenue of the company’s main product, quadruple seedlings, increased by approximately approx.
The chairman of Kangtai Bio is Du Weimin, male, 59 years old, with a master’s degree; the president is Miao Xiang, male, 49 years old, with a master’s degree.
1. In the past 30 days, the shareholding of Kangtai Biotech has decreased by 5,759,100 shares from northbound funds, accounting for a 1.17% decrease in the proportion of tradable shares;
2. In the past 30 days, no institution has conducted research on Kangtai Biology;
3. According to the forecasts of major securities companies on the net profit of Kangtai Bio, the average predicted net profit of Kangtai Bio in the first quarter of 2022 is 426 million yuan. Kangtai Bio’s net profit in the same period last year was 25.1526 million yuan.
(Reporter Wang Xiaobo)
Disclaimer: The content and data in this article are for reference only and do not constitute investment advice. Please verify before use. Do so at your own risk.
Copyright Notice
1This article is an original work of “Daily Economic News”.
2
Without the authorization of “Daily Economic News”, it may not be used in any way, including but not limited to reprinting, excerpting, copying or creating mirror images, etc. Violators will be held accountable.
3Copyright cooperation telephone: 021-60900099.